AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00524745 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
Study NCT03318640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
Study NCT02759146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
Study NCT02759146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditative Practices
Description: Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
Study NCT01842620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral antidiabetic agent
Study NCT01842620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral antidiabetic agent
Study NCT02984826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
Study NCT02984826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic and posture
Description: The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
Study NCT03552549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
Study NCT03552549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTRON A
Description: Interferon alfa-2b, recombinant for intravenous injection.
Study NCT01386099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSN821
Description: Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
Study NCT01386099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 12 weeks.
Study NCT02868723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Management
Description: With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
Study NCT00109486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Study NCT01321697 — intervention group
Intervention type: PROCEDURE
Intervention: Routine Leg edema and groin dissection
Description: The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
Study NCT01732679 — intervention group
Intervention type: OTHER
Intervention: rehabilitation
Description: Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
Study NCT05730452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-stratified discharge and post-discharge care
Description: Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)
Study NCT00359671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6592
Description: MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
Study NCT00359671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK6592
Description: MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
Study NCT00359671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: comparator: docetaxel
Description: docetaxel, delivered as a standard IV infusion.
Study NCT00120315 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: esomeprazole
Description: esomeprazole, original Nexium, 40 mg pills Up to once a day
Study NCT00120315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole, original Nexium, 40 mg pills Up to once a day
Study NCT00120315 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Helicobacter pylori c-13 breath test
Description: Breath test done at entry to find Helicobacter pylori
Study NCT00120315 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Helicobacter pylori c-13 breath test
Description: Breath test done at entry to find Helicobacter pylori
Study NCT02853916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg InSea2®
Study NCT02853916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 250 mg InSea2®
Study NCT02853916 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00243152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: : 25mg and 50mg tablets
Study NCT03497078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bone scintigraphy
Description: Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
Study NCT00243152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Lamotrigine)
Description: Sugar pill manufactured to mimic Lamotrigine tablets
Study NCT02749591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
Study NCT02749591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
Study NCT02749591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Description: After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
Study NCT02749591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
Study NCT02749591 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
Study NCT04083443 — intervention group
Intervention type: OTHER
Intervention: Additional blood sampling
Description: Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
Study NCT03430011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCARH125
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
Study NCT03430011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCARH125 + anakinra
Description: Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
Study NCT03799848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral tablet
Study NCT03393481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: MAA868 dose 1 and dose 2, single administration, subcutaneous,
Study NCT03393481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg, o.d X 10 days
Study NCT04223583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
Study NCT01337882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm venous occlusion plethysmography study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
Study NCT05136807 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study NCT05136807 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01085435 — intervention group
Intervention type: DEVICE
Intervention: S-ICD System
Description: The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
Study NCT02518412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
Study NCT02518412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tDCS
Description: Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
Study NCT00167557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: 180mcg SC weekly starting 30 days post transplant
Study NCT00167557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
Study NCT00167557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: Liver biopsies performed at 9 points in time from time of liver transplant
Study NCT00635791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given by mouth
Study NCT00635791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given by mouth
Study NCT00761579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
Study NCT00877110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Description: Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
Study NCT02672280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Collagen Membrane with MSC
Study NCT02672280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Collagen Membrane
Study NCT01310881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSI-189 Phosphate
Description: Once daily oral administration
Study NCT04512170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC585
Description: single or Mulltiple doses up to 10 days
Study NCT04512170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single or Mulltiple doses up to 10 days
Study NCT04446572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius CECT5713
Description: Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).
Study NCT01025154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Induction Cycle: 20 mg/m\^2 IV over approximately 1 hour daily for 5 days (days 1-5)
Study NCT01025154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction Cycle: 10 mg/m\^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
Study NCT01025154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Cycle: 1 g/m\^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
Study NCT01810432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT01810432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat Meal
Description: Administered orally, at breakfast.
Study NCT02586051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams (mg) IV infusion.
Study NCT02586051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).
Study NCT01995630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Tecnis ZA9003
Study NCT01995630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMO Tecnis ZA9003
Study NCT01995630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO Sensar AR40e
Study NCT01995630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMO Sensar AR40e
Study NCT01431131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrasocket graft
Description: Intrasocket mineralized cancellous allograft
Study NCT01431131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrasocket plus facial overlay graft
Description: Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
Study NCT03111173 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Device
Description: MyECG E3.80 Holter Recorder
Study NCT00968318 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excision of strip of deep fascia
Description: operative technique to excise deep fascia.
Study NCT01455831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
Study NCT01455831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
Study NCT01969890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Description: Zarzio - 5 microg/kg bis in die for 6 days
Study NCT01358916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mailing of antibiotic therapy guidelines to the sentinel physicians
Description: Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
Study NCT01387490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Scheduled Telephone Support (ISTS)
Description: ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
Study NCT03743610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated altitude
Description: Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
Study NCT01387490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
Study NCT04238624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Participants will receive dabrafenib 150 mg orally twice a day
Study NCT03743610 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulated altitude
Description: Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
Study NCT04238624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Participants will receive trametinib 2 mg orally once a day
Study NCT06572462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individualized ATG dosing strategy
Description: Investigators quantified active ATG exposure in 106 haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) recipients, who received a conventional fixed dose of 10 mg/kg ATG during conditioning, the optimal concentration range of active ATG-AUC was determined through the application of machine learning methods, was found to be 100-148.5 × 10\^3 UE·d/L. This concentration range was associated with a reduction in CMV/EBV reactivation, without an increase in acute GVHD or malignant disease relapse. Mathematical function was then exploited to determine the total targeted ATG dose on -3days to -2days based on concentrations of active ATG on -5daysto -4days. Based on this function, investigators established a dosing strategy that aimed to maintain the active ATG-AUC within the optimal range.
Study NCT01144949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silodosin
Description: one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks